Biopharma Scholar Rock Q2 net loss widens, no revenue

Scholar Rock Holding

06/08/2025 12:14

Overview

Scholar Rock reports Q2 net loss of $110 mln, no revenue recorded

Cash reserves expected to support operations into 2027

Result Drivers

COSTS INCREASE - R&D costs increase $20 mln was due to higher drug supply manufacturing costs, employee related expenses

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Income
-$110.03 mln
Q2 Basic EPS
-$0.98
Q2 Income from Operations
-$112.11 mln
Q2 Operating Expenses
$112.11 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Scholar Rock Holding Corp is $52.00, about 28.9% above its August 5 closing price of $36.98

Press Release: ID:nBw4FqHdYa

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)